Suppr超能文献

对疑似患有遗传性乳腺癌/卵巢癌的日本患者进行种系BRCA1和BRCA2突变的横断面分析。

Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer.

作者信息

Sugano Kokichi, Nakamura Seigo, Ando Jiro, Takayama Shin, Kamata Hiroyuki, Sekiguchi Isao, Ubukata Megumi, Kodama Tetsuro, Arai Masami, Kasumi Fujio, Hirai Yasuo, Ikeda Tadashi, Jinno Hiromitsu, Kitajima Masaki, Aoki Daisuke, Hirasawa Akira, Takeda Yuko, Yazaki Kumiko, Fukutomi Takashi, Kinoshita Takayuki, Tsunematsu Ryuichiro, Yoshida Teruhiko, Izumi Masako, Umezawa Shino, Yagata Hiroshi, Komatsu Hiroko, Arimori Naoko, Matoba Noriko, Gondo Nobuhisa, Yokoyama Shiro, Miki Yoshio

机构信息

Oncogene Research Unit/Cancer Prevention Unit, Tochigi Cancer Center Research Institute, Tochigi, Japan.

出版信息

Cancer Sci. 2008 Oct;99(10):1967-76. doi: 10.1111/j.1349-7006.2008.00944.x.

Abstract

The prevalence of BRCA1/2 germline mutations in Japanese patients suspected to have hereditary breast/ovarian cancer was examined by a multi-institutional study, aiming at the clinical application of total sequencing analysis and validation of assay sensitivity in Japanese people using a cross-sectional approach based on genetic factors estimated from personal and family histories. One hundred and thirty-five subjects were referred to the genetic counseling clinics and enrolled in the study. Full sequencing analysis of the BRCA1/2 gene showed 28 types of deleterious mutations in 36 subjects (26.7%), including 13 types of BRCA1 mutations in 17 subjects (12.6%) and 15 types of BRCA2 mutations in 19 subjects (14.1%). Subjects were classified into five groups and 22 subgroups according to their personal and family history of breast and/or ovarian cancer, and the prevalence of deleterious mutations was compared with previously reported data in non-Ashkenazi individuals. Statistical analysis using the Mantel-Haenszel test for groups I through IV revealed that the prevalence of Japanese subjects was significantly higher than that of non-Ashkenazi individuals (P = 0.005, odds ratio 1.87, 95% confidence interval 1.22-2.88). Family history of the probands suffering from breast cancer indicated risk factors for the presence of deleterious mutations of BRCA1/2 as follows: (1) families with breast cancer before age 40 within second degree relatives (P = 0.0265, odds ratio 2.833, 95% confidence interval 1.165-7.136) and (2) families with bilateral breast cancer and/or ovarian cancer within second degree relatives (P = 0.0151, odds ratio 2.88, 95% confidence interval 1.25-6.64).

摘要

一项多机构研究对疑似患有遗传性乳腺癌/卵巢癌的日本患者中BRCA1/2种系突变的患病率进行了检测,旨在通过基于个人和家族病史估计的遗传因素,采用横断面方法,将全序列分析应用于临床,并验证日本人检测灵敏度。135名受试者被转介到遗传咨询诊所并纳入研究。BRCA1/2基因的全序列分析显示,36名受试者(26.7%)中有28种有害突变类型,其中17名受试者(12.6%)有13种BRCA1突变类型,19名受试者(14.1%)有15种BRCA2突变类型。根据受试者的乳腺癌和/或卵巢癌个人和家族病史,将其分为五组和22个亚组,并将有害突变的患病率与之前报道的非阿什肯纳齐人的数据进行比较。使用Mantel-Haenszel检验对第一组至第四组进行统计分析,结果显示日本受试者的患病率显著高于非阿什肯纳齐人(P = 0.005,优势比1.87,95%置信区间1.22 - 2.88)。先证者患有乳腺癌的家族史表明BRCA1/2有害突变存在的危险因素如下:(1)二级亲属中有40岁前患乳腺癌的家族(P = 0.0265,优势比 = 2.833,95%置信区间1.165 - 7.136);(2)二级亲属中有双侧乳腺癌和/或卵巢癌的家族(P = 0.0151,优势比2.88,95%置信区间1.25 - 6.64)。

相似文献

8
Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
J Clin Oncol. 2001 Apr 15;19(8):2247-53. doi: 10.1200/JCO.2001.19.8.2247.
9
Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan.
Am J Hum Genet. 2002 Sep;71(3):595-606. doi: 10.1086/342506. Epub 2002 Aug 13.
10

引用本文的文献

1
Correlation between BRCA1 expression and the advanced stage of triple‑negative breast cancer.
Mol Clin Oncol. 2025 Jan 30;22(4):32. doi: 10.3892/mco.2025.2827. eCollection 2025 Apr.
2
Metastatic breast cancer with double heterozygosity for the and genes responding to olaparib: A case report.
Oncol Lett. 2024 Apr 9;27(6):253. doi: 10.3892/ol.2024.14387. eCollection 2024 Jun.
4
The pathogenic role of the BRCA2 c.7847C>T (p.Ser2616Phe) variant in breast and ovarian cancer predisposition.
Cancer Sci. 2023 Jul;114(7):2993-3002. doi: 10.1111/cas.15799. Epub 2023 Apr 17.
5
Using species richness calculations to model the global profile of unsampled pathogenic variants: Examples from BRCA1 and BRCA2.
PLoS One. 2023 Feb 8;18(2):e0278010. doi: 10.1371/journal.pone.0278010. eCollection 2023.
9
Clinical practice guidelines for high-resolution breast PET, 2019 edition.
Ann Nucl Med. 2021 Mar;35(3):406-414. doi: 10.1007/s12149-021-01582-y. Epub 2021 Jan 25.
10
Germline multigene panel testing revealed a pathogenic variant in a patient with suspected Lynch syndrome.
Int Cancer Conf J. 2020 Oct 9;10(1):6-10. doi: 10.1007/s13691-020-00449-9. eCollection 2021 Jan.

本文引用的文献

2
Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups.
JAMA. 2007 Dec 26;298(24):2869-76. doi: 10.1001/jama.298.24.2869.
6
Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification.
Br J Cancer. 2004 Sep 13;91(6):1155-9. doi: 10.1038/sj.bjc.6602121.
7
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
J Clin Oncol. 2004 Jun 15;22(12):2328-35. doi: 10.1200/JCO.2004.04.033.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验